BerGenBio ASA
Norway · Biopharma, Biotechnology, Health Care
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and s
Key facts
- Headquarters
- Norway
- Employees
- 24
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- www.bergenbio.com
- Company page
Recent activity at BerGenBio ASA
Leadership
- Olav Hellebø, Chief Executive Officer
- Rune Skeie, Chief Financial Officer
- David Colpman, Board Member
- Cristina Oliva, Chief Medical Officer
- Gayle Mills, Chief Business Officer
- Martin Olin, Chief Executive Officer
Verified email and direct lines for BerGenBio ASA’s decision-makers are on Fundz. See plans
BerGenBio ASA in the news
- BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent - Fierce Biotech (Jul 01, 2025)
- BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting - Lelezard (Oct 02, 2019)
- FDA Grants Fast Track Designation to Bemcentinib for STK11-Mutated Advanced/Metastatic NSCLC - CancerNetwork (Nov 09, 2021)
Companies similar to BerGenBio ASA
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- OnCusp Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Dimerix Limited · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Cantargia AB · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- NRx Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About BerGenBio ASA: questions and answers
What does BerGenBio ASA do?
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and s
Where is BerGenBio ASA headquartered?
BerGenBio ASA is headquartered in Norway.
How many employees does BerGenBio ASA have?
BerGenBio ASA has about 24 employees.
Who leads BerGenBio ASA?
Olav Hellebø is a Chief Executive Officer at BerGenBio ASA.
What is the latest news on BerGenBio ASA?
On Nov 20, 2024, BerGenBio Appoints Olav Hellebø as CEO
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy